Cytokinetics, Incorporated - Common Stock — Cash Flow (NASDAQ:CYTK)

Financials

Cash from operating activities 8.94 M-142.52 M-299.52 M-414.33 M-395.89 M-510.01 M -523.85 M Cash from investing activities -196.51 M-147.78 M-262.13 M239.25 M-553.1 M16.67 M 56.2 M Cash from financing activities 234.12 M319.98 M516.17 M221.32 M930.61 M524.46 M 527.47 M Free cash flow 8.94 M-142.52 M-299.52 M-414.33 M-395.89 M-510.01 M -523.85 M

Cytokinetics, Incorporated - Common Stock

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

CYTK

Financials

Cytokinetics, Incorporated - Common Stock

News

Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript

Cytokinetics: Aficamten Has Momentum, But The Stock Is Too Expensive (NASDAQ:CYTK)

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints - Cytokinetics (

How This Biotech Scored 'A Clear Win' Where Bristol Myers Failed

Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?

Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates

Can Myqorzo Drive Growth for Cytokinetics Amid Competition?

FOMC To Release Minutes Of March Meeting, Delta Air Lines Earnings In Focus

Will Positive Camzyos Data Strengthen BMY's Cardiovascular Portfolio?

Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?